Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.

Blood Adv · 2022 · PMC8945294 · PMID 34941996

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP = .09so close (0.05 < p ≤ 0.1)

22-26 Furthermore, mutational profiling of pretreatment biopsy samples with matched gene expression data showed a trend toward more non-CR patients in the TP53 mutant group ( P = .09) ( Figure 6G ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.